[29 February 2020] The IBTA’s monthly e-News has been released and has emailed to all subscribers. To sign up to receive your copy, click here.
You can also read the IBTA e-News February 2020 edition in full online here.
Some of the highlights from this month’s round-up:
- A policy review paper developed by a diverse panel of stakeholders and published in The Lancet Oncology has for the first time established international standards for the analysis of quality-of-life and patient-reported outcomes (PRO) in cancer randomised controlled trials.
- A large, retrospective study of newly diagnosed glioblastoma patients published in JAMA Oncology has found that maximal resection of contrast-enhanced tumour was linked with longer overall survival.
- A team of researchers from Canada reports that they have developed an artificial intelligence (AI) system able to predict individual outcomes in patients with meningioma, according to a paper published in npj Digital Medicine.
- Research published in Nature Communications has found that it may be possible to enhance the effectiveness of immunotherapy via activation of a protein called APOBEC3B.
- Lab studies on mice and human cancer cells published in Nature Communications have shown that a modified poliovirus developed as a glioblastoma therapy appears also to have effect as a cancer vaccine on diffuse midline glioma (DMG) brain tumours.
Our monthly e-News highlights items of interest to our international brain tumour community and is emailed to approximately 6,000 recipients. It gives a round-up of the latest research and treatment developments, news about brain tumour patient organisations around the world, and key forthcoming neuro-oncology scientific and patient conferences. You can sign up to receive the e-News every month by registering here.
To see an archive of existing e-News issues, click here.
